Active Ingredient History

  • Now
Duligotuzumab (INN) is a humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER3. It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.   Wikipedia

More Chemistry
duligotuzumab | mehd7945a | rg7597 | rg-7597


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue